Ultimovacs Asa Stock Price To Earnings To Growth
| ULTI Stock | NOK 2.44 0.11 4.31% |
Ultimovacs ASA fundamentals help investors to digest information that contributes to Ultimovacs ASA's financial success or failures. It also enables traders to predict the movement of Ultimovacs Stock. The fundamental analysis module provides a way to measure Ultimovacs ASA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ultimovacs ASA stock.
Ultimovacs |
Ultimovacs ASA Company Price To Earnings To Growth Analysis
Ultimovacs ASA's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Ultimovacs ASA has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all Norway stocks is 100.0% higher than that of the company.
Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Ultimovacs Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 3.35 B | |||
| Shares Outstanding | 34.4 M | |||
| Shares Owned By Insiders | 48.41 % | |||
| Shares Owned By Institutions | 24.83 % | |||
| Price To Book | 7.44 X | |||
| EBITDA | (161.69 M) | |||
| Net Income | (164.72 M) | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 11.95 X | |||
| Total Debt | 457 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 12.47 X | |||
| Book Value Per Share | 14.97 X | |||
| Cash Flow From Operations | (125.83 M) | |||
| Earnings Per Share | (5.09) X | |||
| Target Price | 165.0 | |||
| Number Of Employees | 23 | |||
| Beta | 1.42 | |||
| Market Capitalization | 4.11 B | |||
| Total Asset | 655.54 M | |||
| Net Asset | 655.54 M |
About Ultimovacs ASA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ultimovacs ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultimovacs ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultimovacs ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.